Table 1 Baseline Demographic Characteristics of ESCC Patients who Underwent NCRT
From: Increased resected lymph node stations improved survival of esophageal squamous cell carcinoma
Characteristics | Participants, No. (%) | ||||||
|---|---|---|---|---|---|---|---|
Total Cohort (N = 333) | Number of e-LNS | P Value | Number of ELN | P Value | |||
≤ 9 (n = 108) | > 9 (n = 225) | ≤ 15 (n = 86) | > 15 (n = 247) | ||||
Age, years, median [IQR] | 63[56–68] | 62[55–68] | 63.0[56–68] | 0.502* | 63[55–68] | 63[56-67.5] | 0.754* |
 ≤ 60 | 126(37.8) | 42(38.9) | 84(37.3) | 0.878 | 33(38.4) | 93(37.7) | 1 |
 >60 | 207(62.2) | 66(61.1) | 141(61.1) |  | 53(61.6) | 154(62.3) |  |
Sex | Â | Â | Â | Â | Â | Â | Â |
 Female | 67(20.1) | 21(19.4) | 46(20.4) | 0.947 | 20 (23.3) | 47 (19.0) | 0.493 |
 Male | 266(79.9) | 87(80.6) | 179(79.6) |  | 66 (76.7) | 200 (81.0) |  |
Tumor location | Â | Â | Â | Â | Â | Â | Â |
 Proximal third | 42(12.6) | 8 (7.4) | 34 (15.1) | 0.099 | 5 (5.8) | 37 (15.0) | 0.085 |
 Middle third | 162(48.6) | 59 (54.6) | 103 (45.8) |  | 46 (53.5) | 116 (47.0) |  |
Distal third | 129(38.7) | 41 (38.0) | 88 (39.1) | Â | 35 (40.7) | 94 (38.1) | Â |
Tumor length, cm median [IQR] | 2.00 [0-3.6] | 2.85 [0–4.0] | 2.00 [0-3.5] | 0.114* | 2.50 [0-3.9] | 2.00 [0-3.6] | 0.716* |
Differentiation | Â | Â | Â | Â | Â | Â | Â |
 Gx | 138 (41.4) | 34 (31.5) | 104 (46.2) | 0.033 | 34 (39.5) | 104 (42.1) | 0.374 |
 G1 | 17 (5.1) | 8 (7.4) | 9 (4.0) |  | 7 (8.1) | 10 (4.0) |  |
 G2 | 84 (25.2) | 35 (32.4) | 49 (21.8) |  | 24 (27.9) | 60 (24.3) |  |
 G3 | 94 (28.2) | 31 (28.7) | 63 (28.0) |  | 21 (24.4) | 73 (29.6) |  |
pT | Â | Â | Â | Â | Â | Â | Â |
 0 | 131(39.3) | 34(31.5) | 97(43.1) | 0.022 | 33 (38.4) | 98 (39.7) | 0.712 |
 1 | 43 (12.9) | 14 (13.0) | 29 (12.9) |  | 13 (15.1) | 30 (12.1) |  |
 2 | 45 (13.5) | 11 (10.2) | 34 (15.1) |  | 9 (10.5) | 36 (14.6) |  |
 3 | 114 (34.2) | 49 (45.4) | 65 (28.9) |  | 31 (36.0) | 83 (33.6) |  |
pN | Â | Â | Â | Â | Â | Â | Â |
 0 | 211 (63.4) | 70 (64.8) | 141 (62.7) | 0.647 | 57 (66.3) | 154 (62.3) | 0.809 |
 1 | 80 (24.0) | 26 (24.1) | 54 (24.0) |  | 19 (22.1) | 61 (24.7) |  |
 2 | 33 (9.9) | 8 (7.4) | 25 (11.1) |  | 7 (8.1) | 26 (10.5) |  |
 3 | 9 (2.7) | 4 (3.7) | 5 (2.2) |  | 3 (3.5) | 6 (2.4) |  |
Pathological Stage | Â | Â | Â | Â | Â | Â | Â |
 1 | 163 (48.9) | 48 (44.4) | 115 (51.1) | 0.18** | 46 (53.5) | 117 (47.4) | 0.812** |
 2 | 48 (14.4) | 22 (20.4) | 26 (11.6) |  | 11 (12.8) | 37 (15.0) |  |
 3 | 114 (34.2) | 35 (32.4) | 79 (35.1) |  | 27 (31.4) | 87 (35.2) |  |
 4 | 8 (2.4) | 3 (2.8) | 5 (2.2) |  | 2 (2.3) | 6 (2.4) |  |
TRG | Â | Â | Â | Â | Â | Â | Â |
 0 | 131 (39.3) | 34 (31.5) | 97 (43.1) | 0.16 | 33 (38.4) | 98 (39.7) | 0.769 |
 1 | 40 (12.0) | 12 (11.1) | 28 (12.4) |  | 13 (15.1) | 27 (10.9) |  |
 2 | 124 (37.2) | 47 (43.5) | 77 (34.2) |  | 30 (34.9) | 94 (38.1) |  |
 3 | 38 (11.4) | 15 (13.9) | 23 (10.2) |  | 10 (11.6) | 28 (11.3) |  |
POLS, days, median (IQR) | 11.0 [9-13] | 11.0 [9-12] | 11.0 [9-13] | 0.889* | 10.0 [9-12] | 11.0 [9-13] | 0.446* |
Comorbidity | Â | Â | Â | Â | Â | Â | Â |
 NO | 231 (69.4) | 79 (73.1) | 152 (67.6) | 0.363 | 54(62.8) | 177(71.7) | 0.161 |
 YES | 102 (30.6) | 29 (26.9) | 73 (32.4) |  | 32 (37.2) | 70 (28.3) |  |